YSYutong Shang

Yutong Shang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yutong Shang has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A small-molecule stabilizer of the calpastatin–calpain-2 complex restores mitochondrial function and mitigates neurodegeneration

    by Di Hu, Xiaoyan Sun, Yutong Shang, Kathleen Lundberg, Drew J. Adams, Xin Qi

    Mitochondrial dysfunction and dysregulated proteolysis drive Huntington’s disease (HD), tauopathy, and related neurodegenerative disorders. Calpain-2, a Ca 2+ -activated protease restrained by calpastatin (CAST), is pathologically overactivated, yet no therapies directly target this axis. We identify A36, a brain-penetrant small molecule derived from CHIR99021 that selectively stabilizes the CAST–calpain-2 complex without inhibiting GSK3. A36 acts as a protein-protein interaction stabilizer, enhancing CAST–calpain-2 binding, preventing CAST degradation, and thereby limiting calpain-2 activation and mitochondrial damage. In patients with HD induced pluripotent stem cell–derived neurons and mutant mouse striatal neurons, A36 normalized mitochondrial morphology and membrane potential, reduced oxidative stress, and improved survival. In vivo, A36 displayed favorable pharmacokinetics and central nervous system exposure; treatment reduced striatal neurodegeneration, mutant huntingtin aggregation, and motor deficits in HD R6/2 mice, and lowered phosphorylated tau, neuroinflammation, and cognitive decline in tauopathy PS19 mice. These findings establish pharmacological stabilization of CAST–calpain-2 as a therapeutic strategy and position A36 as a mechanism-selective modulator with broad neurodegenerative disease potential.


  • Open Access

    Reprogramming the neuronal secretory and metabolic machinery using correctors for Alzheimer therapy

    by Cho Won Jin, Yutong Shang, Sushmita Patil, Xin Qi, Bhanu P. Jena

    Alzheimer disease (AD) is a neurodegenerative disorder characterized by memory loss and personality changes, leading to dementia. The primary cause of the cognitive decline that characterizes AD is the loss of neurons, hypothesized as being due to secretory defects in neurotransmitter release and synaptic plasticity. There is growing evidence that in Alzheimer there is impaired neuronal metabolism due to an increase in free radicals and mitochondrial fission, leading to loss in ATP synthesis required for neurotransmission. Therefore, impaired metabolism in neurons may lead to the observed defects in neurotransmitter release, resulting in the loss of neuronal function and connections in regions of the brain involved in memory and reasoning. In our earlier studies, peptide inhibitor targeting oligomeric ATAD3A, a protein essential for mitochondrial fission and bioenergetics, were found to partially rescue from AD, both in AD neurons and AD mice. In the current study in AD neurons, neuronal porosome reconstitution combined with either a linear or circular peptide inhibitor of ATAD3A oligomers, was able to restore AD neurons to near normal levels of viability and greatly reduce oxidative stress in mitochondria. Additionally, the peptide and a small molecule considered safe by the FDA and used as a food additive, were also able to greatly increase viability in AD neurons and provide reduction to near normal levels of mitochondrial oxidative stress. Collectively, these results demonstrate great promise as secretory and metabolic correctors for AD therapy.


  • Open Access

    Proteomimetic polymer blocks mitochondrial damage, rescues Huntington’s neurons, and slows onset of neuropathology in vivo

    by Wonmin Choi, Mara Fattah, Yutong Shang, Matthew P. Thompson, Kendal P. Carrow, Di Hu, Zunren Liu, Michael J. Avram, Keith Bailey, Or Berger, et al.

    Recently, it has been shown that blocking the binding of valosin-containing protein (VCP) to mutant huntingtin (mtHtt) can prevent neuronal mitochondrial autophagy in Huntington’s disease (HD) models. Herein, we describe the development and efficacy of a protein-like polymer (PLP) for inhibiting this interaction in cellular and in vivo models of HD. PLPs exhibit bioactivity in HD mouse striatal cells by successfully inhibiting mitochondrial destruction. PLP is notably resilient to in vitro enzyme, serum, and liver microsome stability assays, which render analogous control oligopeptides ineffective. PLP demonstrates a 2000-fold increase in circulation half-life compared to peptides, exhibiting an elimination half-life of 152 hours. In vivo efficacy studies in HD transgenic mice (R6/2) confirm the superior bioactivity of PLP compared to free peptide through behavioral and neuropathological analyses. PLP functions by preventing pathologic VCP/mtHtt binding in HD animal models; exhibits enhanced efficacy over the parent, free peptide; and implicates the PLP as a platform with potential for translational central nervous system therapeutics.